Finder makes money from featured partners, but editorial opinions are our own.

How to buy Gilead Sciences (GILD) shares in Australia

Learn how to easily invest in Gilead Sciences shares.

Gilead Sciences Inc (GILD) is a leading drug manufacturers - general business with stocks listed in the US. It opened the day at US$66.93 after a previous close of US$66.76. During the day the price has varied from a low of USD66.74 to a high of USD67.565. The latest price was USD66.95 (25 minute delay). Gilead Sciences is listed on the NASDAQ. All prices are listed in US Dollars.

How to buy shares in Gilead Sciences

  1. Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Gilead Sciences. Find the share by name or ticker symbol: GILD. Research its history to confirm it's a solid investment that matches your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Gilead Sciences reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$66.76, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Gilead Sciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Gilead Sciences. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.

Gilead Sciences stock price (NASDAQ:GILD)

Use our graph to track the performance of GILD stocks over time.

Have Gilead Sciences's shares ever split?

Gilead Sciences's shares were split on a 2:1 basis on 27 January 2013. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Gilead Sciences shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Gilead Sciences shares which in turn could have impacted Gilead Sciences's share price.

Gilead Sciences shares at a glance

Information last updated 2024-04-22.
OpenUS$66.93
HighUS$67.565
LowUS$66.74
CloseUS$66.95
Previous closeUS$66.76
Change US$0.19
Change % 0.2846%
Volume 5,563,286
Information last updated 2024-04-17.
52-week rangeUS$66.89 - US$86.979
50-day moving average US$72.5936
200-day moving average US$76.7513
Target priceUS$84.84
PE ratio 14.9578
Dividend yield US$3 (4.58%)
Earnings per share (TTM) US$4.5

Gilead Sciences share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Gilead Sciences price performance over time

Historical closes compared with the last close of $66.95

1 week (2024-04-16) -0.53%
1 month (2024-03-22) -7.80%
3 months (2024-01-23) -15.76%
6 months (2023-10-20) -13.95%
1 year (2023-04-21) -22.66%
2 years (2022-04-22) 7.55%
3 years (2021-04-22) 2.00%
5 years (2019-04-23) 6.20%

Compare trading platforms to buy Gilead Sciences shares

Name Product Standard brokerage for US shares Currency conversion fee Asset class
eToro
Finder AwardExclusive
eToro
US$0
50-150 pips
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get 12 months of investment tracking app Delta PRO for free when you fund your eToro account (T&Cs apply).
CFD service. Capital at risk.
Join the world's biggest social trading network when you trade stocks, commodities and currencies from the one account.
Moomoo Share Trading
US$0.99
55 pips or 0.0055 AUD/USD
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get an additional 30 days on top of the regular brokerage-free period for new accounts. T&Cs apply.
Trade shares on the ASX, the US markets and buy ETFs with Moomoo. Plus join a community over 20 million investors.
Spaceship US Investing
US$0
0.70%
US shares, ETFs
Dive into US markets with $0 brokerage, starting with just a $10 investment.
Unlock US stocks and ETFs with minimal entry barriers, offering straightforward, low-cost options for new and seasoned investors.
Tiger Brokers
Exclusive
Tiger Brokers
US$2
37 pips
ASX shares, Global shares, US shares, ETFs
Finder exclusive: 10 no-brokerage US or ASX market trades in the first 180 days + 7% p.a. on uninvested cash with first deposit of any amount, plus US$30 TSLA + US$30 NVDA shares with deposits up to AU$2000. T&Cs apply.
Trade Australian, US and Asian stocks with no minimum deposit on Tiger Broker’s feature-packed platform.
CMC Invest
Finder Award
CMC Invest
US$0
0.60%
ASX shares, Global shares, Options trading, US shares, ETFs
$0 brokerage on US, UK, Canadian and Japanese markets (FX spreads apply).
Trade over 45,000 shares and ETFs from Australia and 15 major global markets. Plus, buy Aussie shares or ETFs for $0 brokerage up to $1,000 (First buy order of each security, each day - excludes margin loan settled trades).
Webull
US$0.25
0.50% (50 pips)
ASX shares, Global shares, Options trading, US shares, ETFs
Sign up & deposit $200 to get $100 of rewards value, or deposit $1,000 to get $200 worth. Up to $5,450 value available. T&Cs apply.
Trade ASX and US stocks and US options, plus gain access to inbuilt news platforms and educational resources. You can also start trading for less with fractional shares.
Saxo Invested
Saxo Invested
US$1
0.25%
ASX shares, Global shares, Options trading, US shares, ETFs
Access 22,000+ stocks on 50+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
loading
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Gilead Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Gilead Sciences under- or over-valued?

Valuing Gilead Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Gilead Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Gilead Sciences's P/E ratio

Gilead Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 15x. In other words, Gilead Sciences shares trade at around 15x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Gilead Sciences's PEG ratio

Gilead Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.421. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gilead Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Gilead Sciences's EBITDA

Gilead Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$12.5 billion (£10.1 billion).

The EBITDA is a measure of a Gilead Sciences's overall financial performance and is widely used to measure stock profitability.

Gilead Sciences share price volatility

Over the last 12 months, Gilead Sciences's shares have ranged in value from as little as US$66.89 up to US$86.979. A popular way to gauge a stock's volatility is its "beta".

Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gilead Sciences's is 0.203. This would suggest that Gilead Sciences's shares are less volatile than average (for this exchange).

Gilead Sciences financials

Revenue TTM US$27.1 billion
Operating margin TTM 42.21%
Gross profit TTM US$21.6 billion
Return on assets TTM 9.78%
Return on equity TTM 25.54%
Profit margin 20.89%
Book value 18.325
Market capitalisation US$83.9 billion

TTM: trailing 12 months

Gilead Sciences share dividends

43%

Dividend payout ratio: 42.9% of net profits

Recently Gilead Sciences has paid out, on average, around 42.9% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.58% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Gilead Sciences shareholders could enjoy a 4.58% return on their shares, in the form of dividend payments. In Gilead Sciences's case, that would currently equate to about $3 per share.

While Gilead Sciences's payout ratio might seem fairly standard, it's worth remembering that Gilead Sciences may be investing much of the rest of its net profits in future growth.

Gilead Sciences's most recent dividend payout was on 27 March 2024. The latest dividend was paid out to all shareholders who bought their shares by 13 March 2024 (the "ex-dividend date").

Gilead Sciences's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Gilead Sciences.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Gilead Sciences's total ESG risk score

Total ESG risk: 22.15

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Gilead Sciences's overall score of 22.15 (as at 12/31/2018) is pretty good – landing it in it in the 31st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Gilead Sciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Gilead Sciences's environmental score

Environmental score: 0.53/100

Gilead Sciences's environmental score of 0.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Gilead Sciences's social score

Social score: 12.97/100

Gilead Sciences's social score of 12.97 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Gilead Sciences's governance score

Governance score: 7.65/100

Gilead Sciences's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Gilead Sciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Gilead Sciences's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Gilead Sciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Gilead Sciences has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Gilead Sciences Inc was last rated for ESG on: 2019-01-01.

Total ESG score 22.15
Total ESG percentile 30.98
Environmental score 0.53
Environmental score percentile 2
Social score 12.97
Social score percentile 2
Governance score 7.65
Governance score percentile 2
Level of controversy 2

Gilead Sciences overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Stocks similar to Gilead Sciences

Frequently asked questions

More guides on Finder

Ask a Question

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our 1. Terms Of Service and 6. Finder Group Privacy & Cookies Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site